PTPN6 and Alzheimer disease: The increased interaction in situ, even without pervanadate treatment, may be due to a modified activation state of SHP-1 in the brain of individuals with the rs3865444CC genotype, suggesting the importance of molecular changes throughout the AD brain on microglial signaling.